“Patients requiring surgery for esophageal cancer fare better after undergoing a hybrid minimally invasive esophagectomy (HMIO) compared to an open esophagectomy (OO), according to long-term results of the MIRO trial to be presented at the ESMO 2017 Congress in Madrid.
Mature results of the phase 3 study, with follow-up to a median of 48.8 months, demonstrate that the reduced surgical trauma associated with a laparoscopic approach, does not cut corners on safety, said investigator Dr. Guillaume Piessen, from University Hospital C. Huriez, Lille, France.
“In addition to a 69% reduction in major intra- and postoperative morbidity, three-year overall survival was improved in the laparoscopic group, showing that it is an oncologically sound procedure,” Piessen said.
While the survival difference between groups was not statistically significant, he called it “highly clinically relevant.”
MIRO enrolled 207 adult patients from 13 centers with resectable cancers of the middle or lower third of the esophagus.
They were randomized to undergo either HMIO or an OO.
At 30-days, major postoperative morbidity occurred in significantly fewer patients in the HMIO compared to the OO group (35.9% versus 64.4%, odds ratio [OR] 0.31, 95%CI 0.18-0.55; p<0·001).
At three years, there was also a trend in the HMIO group towards improved overall survival and disease-free survival (67.0% versus 55%, p=0.05 and 57% versus 48%, p=0.15).
Commenting on the trial, Prof. Ulrich Güller, from Kantonsspital St. Gallen, Switzerland said: “This represents an extremely important, well-designed and well-conducted study demonstrating that HMIO is an oncologically sound procedure and significantly reduces postoperative morbidity. Based on these results, the HMIO should become the new standard operating procedure for patients with mid and low [esophageal] cancer.”
Güller added, “I think it is key to mention Prof. Christophe Mariette, the first author of this important trial, who sadly passed away one month ago. Prof. Mariette was a model of a surgical scientist and an opinion leader in the field, and his contribution to the MIRO trial was of cardinal importance.”
To read more esophageal cancer news, please visit: SALGI.org/news
Follow The Salgi Esophageal Cancer Research Foundation on Facebook: Facebook.com/SalgiFoundation
Story Source:
Materials above provided by European Society For Medical Oncology (ESMO). Editor Note: Content may be edited.
References
- Abstract 615O_PR ‘Hybrid Minimally Invasive vs. Open Esophagectomy for patients with Esophageal Cancer: Long-term outcomes of a multicentre, open-label, randomized phase III controlled trial, the MIRO trial” will be presented by Dr Guillaume Piessen during Proffered Paper Session ‘Gastrointestinal tumours, non-colorectal 1’ on Friday, 8 September 2017, 14:00 to 15:30 (CEST) in Barcelona Auditorium.
Disclaimer
This post contains information provided by a press release from authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of The Salgi Esophageal Cancer Research Foundation who cannot be held responsible for the accuracy of the data.
The Salgi Esophageal Cancer Research Foundation is a 501 (c) (3) non profit organization as recognized by the Internal Revenue Service.
Content found on Salgi.org is for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The Salgi Esophageal Cancer Research Foundation 